Oruka Therapeutics (NASDAQ:ORKA) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Oruka Therapeutics (NASDAQ:ORKA) released its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16, FiscalAI reports.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA traded down $2.42 during trading hours on Thursday, hitting $31.99. The stock had a trading volume of 394,440 shares, compared to its average volume of 418,557. The stock’s fifty day simple moving average is $32.65 and its 200 day simple moving average is $27.29. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -16.84 and a beta of -0.38. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $36.53.

Analysts Set New Price Targets

ORKA has been the topic of a number of research reports. UBS Group initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They set a “buy” rating and a $45.00 price objective for the company. Wedbush increased their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Piper Sandler started coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the transaction, the insider directly owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 21,000 shares of company stock valued at $663,530. Corporate insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ORKA. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Russell Investments Group Ltd. bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $43,000. Finally, Legal & General Group Plc bought a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $28,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.